These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 318971)

  • 1. Effect of fosfomycin on the fecal microflora of man.
    Hendlin D; Celozzi E; Weissberger B; Foltz EL
    Chemotherapy; 1977; 23 Suppl 1():117-26. PubMed ID: 318971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of the sensitivity to fosfomycin over the past two years.
    Gobernado M; Santos M; Diosdado N; Pérez F
    Chemotherapy; 1977; 23 Suppl 1():99-103. PubMed ID: 832547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility to fosfomycin of hospital strains isolated in Nantes (France). Frequency of mutation to resistance.
    Courtieu AL; Drugeon H; Billaudel S
    Chemotherapy; 1977; 23 Suppl 1():25-36. PubMed ID: 401717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic localization of the resistance to fosfomycin.
    Perea EJ; Daza RM; Mendaza MP
    Chemotherapy; 1977; 23 Suppl 1():127-32. PubMed ID: 318972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosfomycin and plasmidic resistance.
    Baquero F; López-Brea M; Valls A; Cañedo T
    Chemotherapy; 1977; 23 Suppl 1():133-40. PubMed ID: 318973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fosfomycin, antimicrobial activity in vitro and in vivo.
    Goto S
    Chemotherapy; 1977; 23 Suppl 1():63-74. PubMed ID: 401721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosfomycin Etest for Enterobacteriaceae: Interobserver and interlaboratory agreement.
    van Mens SP; Ten Doesschate T; Kluytmans-van den Bergh MFQ; Mouton JW; Rossen JWA; Verhulst C; Bonten MJM; Kluytmans JAJW
    Int J Antimicrob Agents; 2018 Nov; 52(5):678-681. PubMed ID: 29958976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of fosfomycin with other antibiotics.
    Daza R; Moreno-López M; Dámaso D
    Chemotherapy; 1977; 23 Suppl 1():86-92. PubMed ID: 832546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of glucose-6-phosphate and inorganic phosphate on the resistance of Klebsiella species and E. coli towards fosfomycin (author's transl)].
    Hirschl A; Rotter M
    Zentralbl Bakteriol Orig A; 1979 Sep; 244(4):461-9. PubMed ID: 396739
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae.
    Ballestero-Téllez M; Docobo-Pérez F; Rodríguez-Martínez JM; Conejo MC; Ramos-Guelfo MS; Blázquez J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2017 May; 23(5):325-331. PubMed ID: 28062317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of fosfomycin on the intestinal and pharyngeal flora of man.
    Knothe H; Schäfer V; Sammann A; Shah PM
    Infection; 1991; 19(1):18-20. PubMed ID: 2013503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of sensitivity to fosfomycin at Jimenez Diaz Foundation.
    Alés JM
    Chemotherapy; 1977; 23 Suppl 1():94-8. PubMed ID: 401722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fosfomycin, a new antibiotic: in vitro activity compared with mezlocillin, cefuroxime and gentamicin].
    Lindenschmidt EG; Schassan HH
    Immun Infekt; 1980; 8(4):121-6. PubMed ID: 6453080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current aspects of the fecal flora of the newborn without antibiotherapy during the first 7 days of life: Enterobacteriaceae, enterococci, staphylococci].
    Borderon JC; Lionnet C; Rondeau C; Suc AL; Laugier J; Gold F
    Pathol Biol (Paris); 1996 May; 44(5):416-22. PubMed ID: 8758487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.
    de Cueto M; López L; Hernández JR; Morillo C; Pascual A
    Antimicrob Agents Chemother; 2006 Jan; 50(1):368-70. PubMed ID: 16377714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of fosfomycin].
    Tauchnitz C; Ezold R; Gonschorek J
    Z Gesamte Inn Med; 1982 May; 37(9):253-9. PubMed ID: 7048772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3.
    Lee SY; Park YJ; Yu JK; Jung S; Kim Y; Jeong SH; Arakawa Y
    J Antimicrob Chemother; 2012 Dec; 67(12):2843-7. PubMed ID: 22893681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients.
    Linsenmeyer K; Strymish J; Weir S; Berg G; Brecher S; Gupta K
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1134-6. PubMed ID: 26596940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study.
    García-Rodríguez JA; Trujillano Martín I; Baquero F; Cisterna R; Gobernado M; Liñares F; Martín-Luengo F; Piédrola G
    J Chemother; 1997 Dec; 9(6):394-402. PubMed ID: 9491838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.